News

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Research

• Saudi FDA drug approvals and GMP inspections: trend analysis
• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
• Reshaping landscape of Japanese generics market – uncertain future of universal health insurance

General

• Generic drug growth in Brazil and Venezuela
• Market penetration of generic drugs in Mexico and Brazil
• FDA releases one-year progress report for the Generic Drug Cluster
• Pharmaceutical manufacturing companies in Brazil

News

• FDA approves third ustekinumab biosimilar Pyzchiva
• FDA approves first eculizumab biosimilar Bkemv for two rare diseases
• EMA recommends approval of biosimilar bevacizumab Avzivi
• EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva

Research

• Topline results from clinical development programme for candidate biosimilar AVT05 golimumab
• Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
• Tocilizumab and pembrolizumab biosimilar advances for Korean firms
• Unveiling key clinical findings for denosumab biosimilar candidates

General

• Biosimilars approved in the US
• Biosimilars approved in Europe
• Boehringer Ingelheim to expand access to adalimumab biosimilar
• Challenges and progress in the registration of biosimilars in Latin America

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links